What is Aclaris Therapeutics' stock symbol?
Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
Where is Aclaris Therapeutics' stock going? Where will Aclaris Therapeutics' stock price be in 2017?
5 analysts have issued 12 month price objectives for Aclaris Therapeutics' stock. Their forecasts range from $29.00 to $35.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $32.50 in the next twelve months.
When will Aclaris Therapeutics announce their earnings?
Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 21st 2017.
Who owns Aclaris Therapeutics stock?
Aclaris Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (15.32%), Franklin Resources Inc. (7.13%), Perceptive Advisors LLC (5.88%), FMR LLC (2.19%), Marshall Wace LLP (2.18%) and FIL Ltd (2.03%). Company insiders that own Aclaris Therapeutics stock include Albert Cha, Anand Mehra, Fmr Llc, Kamil Ali-Jackson, Ra Capital Management, Llc, Sofinnova Venture Partners Vii, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc.
Who sold Aclaris Therapeutics stock? Who is selling Aclaris Therapeutics stock?
Aclaris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Vivo Capital LLC, FIL Ltd and Franklin Resources Inc.. Company insiders that have sold Aclaris Therapeutics stock in the last year include Anand Mehra, Kamil Ali-Jackson, Ra Capital Management, Llc and Ventures Fund Vii LP Vivo.
Who bought Aclaris Therapeutics stock? Who is buying Aclaris Therapeutics stock?
Aclaris Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, EcoR1 Capital LLC, Acuta Capital Partners LLC, Marshall Wace LLP, Deerfield Management Co., Renaissance Technologies LLC, Foresite Capital Management III LLC and Alyeska Investment Group L.P.. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Albert Cha, Fmr Llc, Ra Capital Management, Llc, Sofinnova Venture Partners Vii and Vivo Ventures Vii, Llc.
How do I buy Aclaris Therapeutics stock?
Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Aclaris Therapeutics stock cost?
One share of Aclaris Therapeutics stock can currently be purchased for approximately $30.80.